Ontology highlight
ABSTRACT:
SUBMITTER: Yamamoto R
PROVIDER: S-EPMC7248042 | biostudies-literature | 2020 Jun
REPOSITORIES: biostudies-literature
Yamamoto Ryohei R Imai Enyu E Maruyama Shoichi S Yokoyama Hitoshi H Sugiyama Hitoshi H Nitta Kosaku K Tsukamoto Tatsuo T Uchida Shunya S Takeda Asami A Sato Toshinobu T Wada Takashi T Hayashi Hiroki H Akai Yasuhiro Y Fukunaga Megumu M Tsuruya Kazuhiko K Masutani Kosuke K Konta Tsuneo T Shoji Tatsuya T Hiramatsu Takeyuki T Goto Shunsuke S Tamai Hirofumi H Nishio Saori S Shirasaki Arimasa A Nagai Kojiro K Yamagata Kunihiro K Hasegawa Hajime H Yasuda Hideo H Ichida Shizunori S Naruse Tomohiko T Nishino Tomoya T Sobajima Hiroshi H Tanaka Satoshi S Akahori Toshiyuki T Ito Takafumi T Terada Yoshio Y Katafuchi Ritsuko R Fujimoto Shouichi S Okada Hirokazu H Ishimura Eiji E Kazama Junichiro J JJ Hiromura Keiju K Mimura Tetsushi T Suzuki Satoshi S Saka Yosuke Y Sofue Tadashi T Suzuki Yusuke Y Shibagaki Yugo Y Kitagawa Kiyoki K Morozumi Kunio K Fujita Yoshiro Y Mizutani Makoto M Shigematsu Takashi T Kashihara Naoki N Sato Hiroshi H Matsuo Seiichi S Narita Ichiei I Isaka Yoshitaka Y
Clinical and experimental nephrology 20200307 6
<h4>Background</h4>Despite recent advances in immunosuppressive therapy for patients with primary nephrotic syndrome, its effectiveness and safety have not been fully studied in recent nationwide real-world clinical data in Japan.<h4>Methods</h4>A 5-year cohort study, the Japan Nephrotic Syndrome Cohort Study, enrolled 374 patients with primary nephrotic syndrome in 55 hospitals in Japan, including 155, 148, 38, and 33 patients with minimal change disease (MCD), membranous nephropathy (MN), foca ...[more]